alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
**Exhibit 31.2**

 

**CERTIFICATION**

 

I, Richard J.Baum, certify that:

 

1. I havereviewed this quarterly report on Form 10-Q of Ebix, Inc.;

 

2. Based on myknowledge, this report does not contain any untrue statement of a material factor omit to state a material fact necessary to make the statements made, inlight of the circumstances under which such statements were made, notmisleading with respect to the period covered by this report;

 

3. Based on myknowledge, the financial statements, and other financial information includedin this report, fairly present in all material respects the financialcondition, results of operations and cash flows of the registrant as of, andfor, the periods presented in this report;

 

4. Theregistrant’s other certifying officer and I are responsible for establishingand maintaining disclosure controls and procedures (as defined in Exchange ActRules 13a-15(e) and 15d-15(e)) for the registrant and have:

 

(a) Designedsuch disclosure controls and procedures, or caused such disclosure controls andprocedures to be designed under our supervision, to ensure that materialinformation relating to the registrant, including its consolidatedsubsidiaries, is made known to us by others within those entities, particularlyduring the period in which this report is being prepared;

 

(b) Evaluatedthe effectiveness of the registrant’s disclosure controls and procedures andpresented in this report our conclusions about the effectiveness of thedisclosure controls and procedures, as of the end of the period covered by thisreport based on such evaluation; and

 

(c) Disclosedin this report any change in the registrant’s internal control over financialreporting that occurred during the registrant’s most recent fiscal quarter (theregistrant’s fourth fiscal quarter in the case of an annual report) that hasmaterially affected, or is reasonably likely to materially affect, theregistrant’s internal control over financial reporting; and

 

5. Theregistrant’s other certifying officer and I have disclosed, based on our mostrecent evaluation of internal control over financial reporting, to theregistrant’s auditors and the audit committee of the registrant’s board ofdirectors (or persons performing the equivalent functions):

 

(a) Allsignificant deficiencies and material weaknesses in the design or operation ofinternal control over financial reporting which are reasonably likely toadversely affect the registrant’s ability to record, process, summarize andreport financial information; and

 

(b) Any fraud,whether or not material, that involves management or other employees who have asignificant role in the registrant’s internal control over financial reporting.

 

 
| Date:  | May 12, 2005            | /s/ Richard J. Baum |   |
|--------|-------------------------|---------------------|--------|
|   | Richard J. Baum         |
|   | Chief Financial Officer |

 

----
Editorial Note on Part 892
Editorial Note: Nomenclature changes to part 892 appear at 73 FR 35341, June 23, 2008.

§ 892.1760 Diagnostic x-ray tube housing assembly. ( a ) *Identification.* A diagnostic x-ray tube housing assembly is an x-ray generating tube encased in a radiation-shielded housing that is intended for diagnostic purposes. This generic type of device may include high voltage and filament transformers or other appropriate components.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter, subject to the limitations in § 892.9.
[53 FR 1567, Jan. 20, 1988, as amended at 61 FR 1125, Jan. 16, 1996; 66 FR 38819, July 25, 2001]
§ 58.31 Testing facility management. For each nonclinical laboratory study, testing facility management shall: ( a ) Designate a study director as described in § 58.33, before the study is initiated.
( b ) Replace the study director promptly if it becomes necessary to do so during the conduct of a study.
( c ) Assure that there is a quality assurance unit as described in § 58.35.
( d ) Assure that test and control articles or mixtures have been appropriately tested for identity, strength, purity, stability, and uniformity, as applicable.
( e ) Assure that personnel, resources, facilities, equipment, materials, and methodologies are available as scheduled.
( f ) Assure that personnel clearly understand the functions they are to perform.
( g ) Assure that any deviations from these regulations reported by the quality assurance unit are communicated to the study director and corrective actions are taken and documented.
[43 FR 60013, Dec. 22, 1978, as amended at 52 FR 33780, Sept. 4, 1987]
Editorial Note on Part 874
Editorial Note: Nomenclature changes to part 874 appear at 73 FR 35341, June 23, 2008.

§ 874.3325 Self-fitting air-conduction hearing aid. ( a ) *Identification.* A self-fitting air-conduction hearing aid is a wearable sound amplifying device that is intended to compensate for impaired hearing and incorporates technology, including software, that allows users to program their hearing aids. This technology integrates user input with a self-fitting strategy and enables users to independently derive and customize their hearing aid fitting and settings. A self-fitting air-conduction hearing aid is subject to the requirements in § 800.30 or § 801.422 of this chapter, as applicable.
( b ) *Classification.* Class II (special controls). The special controls for this device are: ( 1 ) Clinical data must evaluate the effectiveness of the self-fitting strategy.
( 2 ) Electroacoustic parameters, including maximum output limits, distortion levels, self-generated noise levels, latency, and frequency response, must be specified and tested.
( 3 ) Performance data must demonstrate the electromagnetic compatibility (EMC), electrical safety, and thermal safety of the device.
( 4 ) Software verification, validation, and hazard analysis must be performed.
( 5 ) If the device incorporates wireless technology: ( i ) Performance testing must validate safety of exposure to non-ionizing radiation; and
( ii ) Performance data must validate wireless technology functions.
( 6 ) Usability testing must demonstrate that users can correctly use the device as intended under anticipated conditions of use.
[84 FR 57612, Oct. 28, 2019, as amended at 87 FR 50762, Aug. 17, 2022]
Order entered September 16, 2016

In The 

## Court of Appeals Fifth District of Texas at Dallas

No. 05
- 16
- 01095
- CV IN RE: CC FORBES, LL C'S AND DEFENDANTS F ORBES ENERGY SERVICE S, LTD,

FORBES ENERGY SERVI CES DELAWARE, LLC, AND TX ENERGY SERVIC ES, LLC, Rela t ors Original proceeding from the 191st Judicial District Court

Dallas County, Texas Trial Court Cause No. DC
- 14
- 12627



### O RDER Before the Court is relators’ September 15, 2016 emergency motion for tempo rary relief.
We GRANT the motion and STAY the trial court’s September 12, 2016 order granting the motion to compel the depositions of John Crisp and Charles Forbes, Jr. Such stay shall remain in effect unti l further order of this Court. The Court further requests respondent and the real parties in interest to file their responses, if any, to relators’ September 15, 2016 petition for writ of mandamus by September 26, 2016.

/s/ BILL WHITEHILL JUSTICE
SAT Report

PMN Number: P-15-0188

SAT Date: 1/27/2015

Print Date: 5/8/2015

Related cases: Yes

Health related cases: 

Ecotox related cases: 

Concern levels:

Type of Concern: Health Eco Comments

Level of Concern: 1-2 3

 Persistence Bioaccum Toxicity Comments

3 11

Exposure Based Review:

Health:

Ecotox: No

Routes of exposure: Health: Dermal Drinking Water Inhalation 

Ecotox: All releases to water

Fate: ;

Keywords:

 Keywords: AQUATOX; IRR; MUTA; SENS

Summary of Assessment:

 Fate:

Fate Summary: P-15-0188

FATE: 

Liquid with MP < 25 C (E)

S = 0.16 mg/L at 25 °C (E)

VP < 1.0E-6 torr at 25 C (E)

BP > 400 C (E)

H < 1.00E-8 (E)

POTW removal (%) = 90 via sorption

Time for complete ultimate aerobic biodeg > mo

Sorption to soils/sediments = v.strong
PBT Potential: P3B1

*CEB FATE: Migration to ground water = negl

 Health:

 Health Summary: Absorption 

is poor all routes (analogue). There is uncertain concern for irritation 

and concern for mutagenicity and sensitization based on the methacrylate moiety. 

 Ecotox:

Test Organism Test 

Type

Test End 

Point

Predicted Measured Comments

fish 96-h LC50 0.96 or *

daphnid 48-h LC50 0.88 or *

green algal 96-h EC50 0.20

fish _ chronic value 0.071

daphnid _ chronic 

value

0.10

algal _ chronic 

value

0.11

Sewage Sludge 3-h EC50

Sewage Sludge _ Chronic 

Value

_

Ecotox Values Comments: Predictions are based on SARs for methacrylates; SAR chemical 

class = methacrylate; MW liquid with unknown mp 

(P); log Kow = 5.07 (EPI, n=0); S = 0.16 mg/L at 20 C (P, n=0); pH7; effective concentrations 

based on 100% active ingredients and mean measured concentrations; hardness <150.0 mg/L as 

CaCO3; and TOC <2.0 mg/L;

Factors Values Comments

Assessment Factor 10

Concentration of Concern 

(ppb) 

Acute 

Concentration of Concern 

(ppb) Chronic

7

SARs methacrylates

SAR Class methacrylate

New Chemcial Category Acrylates/Methacrylates

Ecotox Factors Comments: 

 SAT Chair:
<PAGE>

                                                                    Exhibit 99.2


                            CERTIFICATION PURSUANT TO
                             18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002


In connection with the quarterly report on Form 10-Q of Biopure Corporation for
the period ended April 30, 2003, I, Ronald F. Richards, Chief Financial
Officer, hereby certify, to the best of my knowledge, pursuant to 18 U.S.C.
1350, as adopted pursuant to 906 of the Sarbanes-Oxley Act of 2002, that:

     (1) the Form 10-Q for the period ended April 30, 2003, fully complies
with the requirements of section 13(a) or 15(d) of the Securities Exchange Act
of 1934; and

     (2) the information contained in the Form 10-Q for the period ended April
30, 2003 fairly presents, in all material respects, the financial condition and
results of operations of Biopure Corporation.


/s/ Ronald F. Richards
---------------------------------------
Ronald F. Richards
Chief Financial Officer
June 16, 2003
Editorial Note on Part 886
Editorial Note: Nomenclature changes to part 886 appear at 73 FR 35341, June 23, 2008.

§ 886.1860 Ophthalmic instrument stand. ( a ) *Identification.* An ophthalmic instrument stand is an AC-powered or nonpowered device intended to store ophthalmic instruments in a readily accessible position.
( b ) *Classification.* Class I (general controls). The AC-powered device and the battery-powered device are exempt from the premarket notification procedures in subpart E of part 807 of this chapter, subject to the limitations in § 886.9. The battery-powered device is also exempt from the current good manufacturing practice requirements of the quality system regulation in part 820 of this chapter, with the exception of § 820.180, with respect to general requirements concerning records, and § 820.198, with respect to complaint files.
[55 FR 48442, Nov. 20, 1990, as amended at 59 FR 63013, Dec. 7, 1994; 66 FR 38812, July 25, 2001]
EPA Registration Jacket 39578-1 














































47

*Commercial/financial information may be entitled to confidential treatment* 
48





















70

*Commercial/financial information may be entitled to confidential treatment* 
71
72
#### Gibbs Estate

*J. Montgomery Forster*and *Charles Myers,*for accountant.

*Elgin E. Weest,*for Commonwealth.

December 28, 1951.

van Roden, P. J.,

Decedent died March 2, 1950, survived by neither spouse nor issue. By three separate wills, each dated September 24, 1947, decedent purported to dispose of his estates in England, Canada and the United States of America respectively. . . .

*48The inheritance tax due the Commonwealth of Pennsylvania has been paid to the extent of $33,781.51 as indicated by the receipts for tax submitted for the court’s inspection. However, counsel for the Commonwealth appeared at the audit and stated that a supplemental inventory and appraisement had been filed and that there may be additional tax due in connection therewith. Likewise, it was stated at the time of audit, that a question has arisen as to whether in appraising the value of decedent’s assets subject to Pennsylvania transfer inheritance tax, should there be deducted administration expenses and debts incurred in Canada and England, and taxes on the transfer of stocks and bonds of Canadian corporations, bonds of the Dominion of Canada, Canadian bank accounts and English securities paid to the Dominion of Canada, the Provinces of Ontario and Quebec, and Great Britain. Subsequently, under date of December 12, 1951, counsel for the Commonwealth informed the court that he had received an opinion from Deputy Attorney General Francis J. Gafford, stating that payment of taxes imposed by Canada were proper deductions in computing the clear value of decedent’s estate, and that the administration expenses actually paid in Canada and England are likewise allowable deductions under our statute. Accordingly, the court holds that the accountant must be allowed deductions for foreign taxes and administration expenses in the computation of the inheritance tax. However, inasmuch as the supplemental inventory listed an American asset stated to be of no value, and it appears that the Commonwealth has not yet had an opportunity to make another appraisement of such asset, this adjudication is made subject to the payments of such additional inheritance tax, if any, as may properly be found to be due. . . .
Exhibit 31.a

I, John P. Manning, certify that:

1. I have reviewed this quarterly report on Form 10-Q of American Affordable Housing II Limited Partnership;
2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:



1. designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
2. evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
3. disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and





1. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):



1. all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
2. any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.





|Date: February 21, 2006 | /s/ John P. Manning        
|----------------------- | ---------------------------
|                        | John P. Manning            
|                        | Principal Executive Officer
|                        |                            
|                        |                            
|                        |
**EXHIBIT 35.1**

** **

**World Omni Financial Corp.**

**Servicer Compliance Statement**

**Pursuant to Item 1123**

**of Regulation AB**

** **

I, William J. Shope, dohereby certify that I am the Vice President and Chief Financial Officer of World Omni Financial Corp., a Florida corporation, andfurther certify on behalf of World Omni Financial Corp. in its capacity as servicer (the “Servicer”) under the ExchangeNote Servicing Supplement 2015-A to Closed-End Servicing Agreement, dated as of July 29, 2015 (the “Exchange Note ServicingSupplement”), among AL Holding Corp., as Closed-End Collateral Agent, World Omni LT, as Titling Trust, and the Servicer,as follows:

 

(i)          A review of theactivities of the Servicer covered by the Exchange Note Servicing Supplement and the Closed-End Servicing Agreement (as definedin the Exchange Note Servicing Supplement) for the fiscal year ended December 31, 2015 (the “Reporting Period”), andof its performance under the Exchange Note Servicing Supplement and the Closed-End Servicing Agreement (as defined in the ExchangeNote Servicing Supplement), has been made under my supervision.

 

(ii)          To the best ofmy knowledge, based on the review described above, the Servicer has fulfilled all of its obligations under the Exchange Note ServicingSupplement and the Closed-End Servicing Agreement (as defined in the Exchange Note Servicing Supplement) in all material respectsthroughout the Reporting Period.

 

IN WITNESS WHEREOF, I have hereuntoset my hand as of March 11, 2016.
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Commodity Futures Trading Commission

The following notice of meeting is published pursuant to the provisions of the Government in the Sunshine Act, Public Law 94-409, 5 U.S.C. 552b.

# Agency Holding the Meeting:

Commodity Futures Trading Commission.

# Time and Date:

1 p.m., January 14, 2010.

# Place:

Three Lafayette Center, 1155 21st St., NW., Washington, DC, Lobby Level Hearing Room (Room 1000).

# Status:

Open.

# Matters to be Considered:

Issuance of a proposed rule on energy position limits and hedge exemptions on regulated futures exchanges, derivatives transaction execution facilities and electronic trading facilities.

# Contact Person for More Information:

David A. Stawick, Secretary of the Commission, 202-418-5071.

David A. Stawick,

Secretary of the Commission.

[FR Doc. 2010-450 Filed 1-8-10; 4:15 pm]

BILLING CODE 6351-01-P
Editorial Note on Part 872
Editorial Note: Nomenclature changes to part 872 appear at 73 FR 35341, June 23, 2008.

§ 872.3760 Denture relining, repairing, or rebasing resin. ( a ) *Identification.* A denture relining, repairing, or rebasing resin is a device composed of materials such as methylmethacrylate, intended to reline a denture surface that contacts tissue, to repair a fractured denture, or to form a new denture base. This device is not available for over-the-counter (OTC) use.
( b ) *Classification.* Class II.
Editorial Note on Part 864
Editorial Note: Nomenclature changes to part 864 appear at 73 FR 35341, June 23, 2008.

§ 864.9700 Blood storage refrigerator and blood storage freezer. ( a ) *Identification.* A blood storage refrigerator and a blood storage freezer are devices intended for medical purposes that are used to preserve blood and blood products by storing them at cold or freezing temperatures.
( b ) *Classification.* Class II (special controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to § 864.9.
[45 FR 60650, Sept. 12, 1980, as amended at 63 FR 59226, Nov. 3, 1998]
<PAGE>

                                                                     Exhibit 4.6


                              CERTIFICATE OF TRUST
                                       OF
                             CHUBB CAPITAL TRUST II


      This CERTIFICATE OF TRUST of Chubb Capital Trust II (the "Trust"), is
being duly executed and filed by the undersigned, as trustees, to form a
statutory trust under the Delaware Statutory Trust Act (12 Del. Code Section
3801 et seq.) (the "Act").

      1. Name. The name of the statutory trust being formed hereby is "Chubb
Capital Trust II."

      2. Delaware Trustee. The name and business address of the trustee of the
Trust with a principal place of business in the State of Delaware is Bank One
Delaware, Inc., Three Christina Centre, 201 North Walnut Street, Wilmington,
Delaware 19801.

      3. Effective Date. This Certificate of Trust shall be effective as of its
filing with the Secretary of the State of Delaware.

      4. Counterparts. This Certificate of Trust may be executed in one or more
counterparts.

..

<PAGE>

      IN WITNESS WHEREOF, the undersigned trustees of the Trust, have executed
this Certificate of Trust in accordance with Section 3811(a) of the Act.


                                    BANK ONE DELAWARE, INC., as Delaware Trustee
                                    of the Trust

                                    By:     /s/ SANDRA L. CARUBA
                                            --------------------------------
                                    Name:   Sandra L. Caruba
                                    Title:  Senior Counsel


                                    BANK ONE TRUST COMPANY, N.A., as Property
                                    Trustee of the Trust

                                    By:     /s/ SANDRA L. CARUBA
                                            --------------------------------
                                    Name:   Sandra L. Caruba
                                    Title:  Senior Counsel


                                    MICHAEL O'REILLY, not in his individual
                                    capacity but solely as Administrative
                                    Trustee of the Trust

                                    By:     /s/ MICHAEL O'REILLY
                                            --------------------------------
                                    Name:   Michael O'Reilly
                                    Title:  Vice Chairman and Chief Financial
                                            Officer